$ALLO
Allogene Therapeutics, Inc. Stock $allo

$allo Overview Financials Valuation SEC Filings Company Website

2021 Q2 Form 10-Q Financial Statement

#000173728721000040 Filed on August 04, 2021

Income Statement

Concept	2021 Q2	2020 Q2	2020 Q1
Revenue	$44.00K	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$18.78M	$15.86M	$15.64M
YoY Change	18.43%	11.77%	19.75%
% of Gross Profit
Research & Development	$52.29M	$47.30M	$42.04M
YoY Change	10.56%	48.85%	79.64%
% of Gross Profit
Depreciation & Amortization	$1.962M	$1.890M	$1.893M
YoY Change	3.81%	64.35%	247.98%
% of Gross Profit
Operating Expenses	$71.07M	$63.16M	$57.68M
YoY Change	12.53%	37.42%	58.2%
Operating Profit	-$71.03M	-$63.16M	-$57.68M
YoY Change	12.46%	37.42%	58.2%
Interest Expense	$624.0K	$2.340M	$3.260M
YoY Change	-73.33%	-48.68%	-32.51%
% of Operating Profit
Other Income/Expense, Net	$93.00K	$2.184M	$3.203M
YoY Change	-95.74%	-52.09%	-33.62%
Pretax Income	-$70.94M	-$60.97M	-$54.48M
YoY Change	16.34%	47.27%	72.21%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$70.94M	-$60.97M	-$54.48M
YoY Change	16.34%	47.84%	72.48%
Net Earnings / Revenue	-161218.18%
Basic Earnings Per Share	-$0.53	-$0.53
Diluted Earnings Per Share	-$0.53	-$0.53	-$500.0K
COMMON SHARES
Basic Shares Outstanding	134.8M shares	115.4M shares	124.9M shares
Diluted Shares Outstanding	134.8M shares	115.4M shares

Balance Sheet

Concept	2021 Q2	2020 Q2	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$587.7M	$899.7M	$492.9M
YoY Change	-34.67%	79.06%	4.78%
Cash & Equivalents	$223.5M	$280.4M	$135.9M
Short-Term Investments	$364.2M	$619.3M	$357.0M
Other Short-Term Assets	$14.46M	$9.900M	$11.50M
YoY Change	46.1%	70.69%	9.52%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$602.2M	$909.6M	$504.4M
YoY Change	-33.8%	77.81%	5.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$125.5M	$84.61M	$66.35M
YoY Change	48.29%	136.21%	224.83%
Goodwill
YoY Change
Intangibles		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Long-Term Investments	$344.3M	$215.5M	$65.00M
YoY Change	59.79%	45.81%	-69.71%
Other Assets	$5.829M	$2.160M	$4.675M
YoY Change	169.86%	-3.49%	982.18%
Total Long-Term Assets	$524.6M	$349.0M	$184.1M
YoY Change	50.32%	56.87%	-32.5%
TOTAL ASSETS
Total Short-Term Assets	$602.2M	$909.6M	$504.4M
Total Long-Term Assets	$524.6M	$349.0M	$184.1M
Total Assets	$1.127B	$1.259B	$688.5M
YoY Change	-10.47%	71.46%	-8.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.01M	$9.057M	$7.199M
YoY Change	21.51%	-61.46%	-44.52%
Accrued Expenses	$34.69M	$31.80M	$19.60M
YoY Change	9.08%	119.31%	37.06%
Deferred Revenue	$305.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$46.00M	$40.90M	$26.82M
YoY Change	12.48%	7.62%	-1.64%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$5.705M	$3.163M	$3.650M
YoY Change	80.37%	-42.44%	-39.82%
Total Long-Term Liabilities	$5.705M	$3.163M	$3.650M
YoY Change	80.37%	-42.44%	-39.82%
TOTAL LIABILITIES
Total Short-Term Liabilities	$46.00M	$40.90M	$26.82M
Total Long-Term Liabilities	$5.705M	$3.163M	$3.650M
Total Liabilities	$102.9M	$95.13M	$82.00M
YoY Change	8.19%	21.39%	20.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$750.3M	-$511.6M	-$450.6M
YoY Change	46.66%	79.91%	85.35%
Common Stock	$1.774B	$1.673B	$1.056B
YoY Change	6.05%	78.41%	14.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.024B	$1.163B	$606.5M
YoY Change
Total Liabilities & Shareholders Equity	$1.127B	$1.259B	$688.5M
YoY Change	-10.47%	71.46%	-8.12%

Cashflow Statement

Concept	2021 Q2	2020 Q2	2020 Q1
OPERATING ACTIVITIES
Net Income	-$70.94M	-$60.97M	-$54.48M
YoY Change	16.34%	47.84%	72.48%
Depreciation, Depletion And Amortization	$1.962M	$1.890M	$1.893M
YoY Change	3.81%	64.35%	247.98%
Cash From Operating Activities	-$41.17M	-$26.72M	-$40.81M
YoY Change	54.07%	7.35%	34.88%
INVESTING ACTIVITIES
Capital Expenditures	-$10.90M	-$16.06M	$12.25M
YoY Change	-32.11%	104.33%	17.56%
Acquisitions
YoY Change
Other Investing Activities	$35.49M	-$412.9M	-$2.750M
YoY Change	-108.6%	-888.77%	-106.35%
Cash From Investing Activities	$24.59M	-$429.0M	-$15.01M
YoY Change	-105.73%	-1064.19%	-145.63%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$14.85M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.218M	600.2M	$16.59M
YoY Change	-99.46%	249970.83%	2324.85%
NET CHANGE
Cash From Operating Activities	-41.17M	-26.72M	-$40.81M
Cash From Investing Activities	24.59M	-429.0M	-$15.01M
Cash From Financing Activities	3.218M	600.2M	$16.59M
Net Change In Cash	-13.36M	144.5M	-$39.23M
YoY Change	-109.25%	628.23%	-1283.05%
FREE CASH FLOW
Cash From Operating Activities	-$41.17M	-$26.72M	-$40.81M
Capital Expenditures	-$10.90M	-$16.06M	$12.25M
Free Cash Flow	-$30.27M	-$10.66M	-$53.06M
YoY Change	183.91%	-37.4%	30.44%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Amendment Flag AmendmentFlag	false
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001737287
	dei	Entity Central Index Key EntityCentralIndexKey	0001737287
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2021Q2	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://allogene.com/20210630#AccruedAndOtherLiabilitiesCurrent
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://allogene.com/20210630#AccruedAndOtherLiabilitiesCurrent
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	41295000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	125459000	USD
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38693
	dei	Entity Registrant Name EntityRegistrantName	Allogene Therapeutics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3562771
	dei	Entity Address Address Line1 EntityAddressAddressLine1	210 East Grand Avenue
	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
	dei	City Area Code CityAreaCode	650
	dei	Local Phone Number LocalPhoneNumber	457-2700
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
	dei	Trading Symbol TradingSymbol	ALLO
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	142183418	shares
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	223503000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	183351000	USD
CY2021Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	364204000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	644559000	USD
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14464000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	17220000	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	602171000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	845130000	USD
CY2021Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	325523000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	204208000	USD
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	39474000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	118840000	USD
CY2021Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	9449000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	9449000	USD
CY2021Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5829000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5169000	USD
CY2021Q2	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	18819000	USD
CY2020Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	3738000	USD
CY2021Q2	us-gaap	Assets Assets	1126724000	USD
CY2020Q4	us-gaap	Assets Assets	1227829000	USD
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	11005000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10390000	USD
CY2021Q2	allo	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	34688000	USD
CY2020Q4	allo	Accrued And Other Liabilities Current AccruedAndOtherLiabilitiesCurrent	44938000	USD
CY2021Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	305000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	38992000	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	45998000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	94320000	USD
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	51209000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	50809000	USD
CY2021Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5705000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3083000	USD
CY2021Q2	us-gaap	Liabilities Liabilities	102912000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	148212000	USD
CY2021Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	142120731	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	142120731	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	140474305	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	140474305	shares
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	142000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	140000	USD
CY2021Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1774298000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1725552000	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-750294000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-646343000	USD
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-334000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	268000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	1023812000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1079617000	USD
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1126724000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1227829000	USD
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	44000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38389000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52290000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	47296000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	107473000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	89337000	USD
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18783000	USD
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15862000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	35146000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	31502000	USD
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	71073000	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	63158000	USD
	us-gaap	Operating Expenses OperatingExpenses	142619000	USD
	us-gaap	Operating Expenses OperatingExpenses	120839000	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-71029000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-63158000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-104230000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-120839000	USD
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	624000	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2340000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1135000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5600000	USD
CY2021Q2	us-gaap	Other Expenses OtherExpenses	531000	USD
CY2020Q2	us-gaap	Other Expenses OtherExpenses	156000	USD
	us-gaap	Other Expenses OtherExpenses	856000	USD
	us-gaap	Other Expenses OtherExpenses	215000	USD
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	93000	USD
CY2020Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2184000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	279000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5385000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-70936000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-60974000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-103951000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-115454000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-233000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	220000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-602000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	685000	USD
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-71169000	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-60754000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-104553000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-114769000	USD
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.53
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.78
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.78
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.53
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.53
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.53
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.03
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	134826805	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	134826805	shares
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	115377210	shares
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115377210	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	133503262	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	133503262	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	112163123	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	112163123	shares
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	1069779000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3214000	USD
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	854000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	21134000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-70936000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-233000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	1023812000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1079617000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7274000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1564000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	37926000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1984000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-103951000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-602000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	1023812000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	606519000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4476000	USD
CY2020Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	710000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16770000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	0	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-60974000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	220000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	1163419000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	629023000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4780000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1419000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	30985000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1438000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-115454000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	685000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	1163419000	USD
	us-gaap	Profit Loss ProfitLoss	-103951000	USD
	us-gaap	Profit Loss ProfitLoss	-115454000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	37926000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	30985000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	151000	USD
	us-gaap	Depreciation Depreciation	3882000	USD
	us-gaap	Depreciation Depreciation	3781000	USD
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-3746000	USD
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-20000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	2394000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	1060000	USD
	allo	Income Loss From Cost Method Investment IncomeLossFromCostMethodInvestment	-857000	USD
	allo	Income Loss From Cost Method Investment IncomeLossFromCostMethodInvestment	-215000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2755000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4116000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	660000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-2458000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1088000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-503000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2470000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	6829000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-38687000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	2622000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-1188000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-90498000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-67530000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	17363000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	28307000	USD
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	15938000	USD
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	USD
	allo	Proceeds From Payments For Sale Of Debt Securities Available For Sale ProceedsFromPaymentsForSaleOfDebtSecuritiesAvailableForSale	-10000	USD
	allo	Proceeds From Payments For Sale Of Debt Securities Available For Sale ProceedsFromPaymentsForSaleOfDebtSecuritiesAvailableForSale	4877000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	484082000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	221633000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	329379000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	642181000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	121392000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-443978000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	7274000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	4780000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1984000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1438000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9258000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	616761000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	40152000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	105253000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	192800000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	179425000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	232952000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	284678000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1706000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	8298000	USD
	us-gaap	Payments For Leasing Costs Commissions And Tenant Improvements PaymentsForLeasingCostsCommissionsAndTenantImprovements	2432000	USD
	us-gaap	Payments For Leasing Costs Commissions And Tenant Improvements PaymentsForLeasingCostsCommissionsAndTenantImprovements	2816000	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-750300000	USD
	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	1111000	USD
	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	1617000	USD
	us-gaap	Nature Of Operations NatureOfOperations	Description of Business<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allogene Therapeutics, Inc. (the Company or Allogene) was incorporated on November 30, 2017 in the State of Delaware and is headquartered in South San Francisco, California. Allogene is a clinical-stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The Company is developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Need for Additional Capital</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has sustained operating losses and expects to continue to generate operating losses for the foreseeable future. The Company’s ultimate success depends on the outcome of its research and development activities as well as the ability to commercialize the Company's product candidates. The Company had cash and cash equivalents and investments of $913.2 million as of June 30, 2021. Since inception through June 30, 2021, the Company has incurred cumulative net losses of $750.3 million. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to raise additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available when needed and at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates. The Company expects that its cash and cash equivalents and investments will be sufficient to fund its operations for a period of at least one year from the date the accompanying unaudited condensed consolidated financial statements are filed with the Securities and Exchange Commission (SEC). </span></div>The Company cannot at this time predict the specific extent, duration, or full impact that the ongoing COVID-19 pandemic will have on its financial condition and operations, including ongoing and planned clinical trials. The impact of the COVID-19 pandemic on the financial performance of the Company will depend on future developments, including the duration and spread of the pandemic and related governmental advisories and restrictions. These developments and the impact of the COVID-19 pandemic on the financial markets and the overall economy are highly uncertain. If business conditions, financial markets and/or the overall economy are impacted for an extended period, the Company’s results may be adversely affected.
CY2021Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	913200000	USD
	us-gaap	Use Of Estimates UseOfEstimates	Use of EstimatesThe preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include but are not limited to the fair value of stock options, fair value of investments, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.
CY2021Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	859346000	USD
CY2021Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	336000	USD
CY2021Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	227000	USD
CY2021Q2	allo	Cash Equivalents And Short Term Investments CashEquivalentsAndShortTermInvestments	859455000	USD
CY2021Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	169728000	USD
CY2021Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	364204000	USD
CY2021Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	325523000	USD
CY2021Q2	allo	Cash Equivalents And Short Term Investments CashEquivalentsAndShortTermInvestments	859455000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	950095000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	764000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	53000	USD
CY2021Q2	us-gaap	Debt Securities Available For Sale Term DebtSecuritiesAvailableForSaleTerm	P3Y
CY2020Q4	allo	Cash Equivalents And Short Term Investments CashEquivalentsAndShortTermInvestments	950806000	USD
CY2020Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	102039000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	644559000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	204208000	USD
CY2020Q4	allo	Cash Equivalents And Short Term Investments CashEquivalentsAndShortTermInvestments	950806000	USD
CY2021Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	0	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	5000000.0	USD
CY2021Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	142249000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	131748000	USD
CY2021Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	16790000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	12908000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	125459000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	118840000	USD
CY2018Q3	allo	Area Of New Office Building AreaOfNewOfficeBuilding	68000	sqft
CY2018Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P127M
CY2018Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P7Y
CY2021Q2	us-gaap	Tenant Improvements TenantImprovements	5000000.0	USD
CY2018Q4	allo	Area Of New Office Building AreaOfNewOfficeBuilding	14943	sqft
CY2018Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P124M
CY2018Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P7Y
CY2018Q4	allo	Tenant Improvement Allowance TenantImprovementAllowance	800000	USD
CY2021Q2	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	5200000	USD
CY2020Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	4300000	USD
CY2021Q2	us-gaap	Variable Lease Cost VariableLeaseCost	204000	USD
CY2020Q2	us-gaap	Variable Lease Cost VariableLeaseCost	399000	USD
CY2021Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	54356000	USD
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3147000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2974000	USD
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	51209000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	50809000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	53783000	USD
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	1853000	USD
CY2020Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	1868000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	3715000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	3736000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	531000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	608000	USD
CY2021Q2	us-gaap	Lease Cost LeaseCost	2057000	USD
CY2020Q2	us-gaap	Lease Cost LeaseCost	2267000	USD
	us-gaap	Lease Cost LeaseCost	4246000	USD
	us-gaap	Lease Cost LeaseCost	4344000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	2400000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	3570000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	7917000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	8168000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	8430000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	8509000	USD
CY2021Q2	allo	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	48143000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	84737000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	30057000	USD
CY2021Q2	allo	Tenant Improvement Allowance TenantImprovementAllowance	325000	USD
CY2021Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	54356000	USD
CY2021Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0842
CY2021Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y18D
CY2020Q3	us-gaap	Lessee Finance Lease Term Of Contract1 LesseeFinanceLeaseTermOfContract1	P20Y
CY2020Q3	allo	Lessee Finance Lease Payment Upon Contract Termination LesseeFinanceLeasePaymentUponContractTermination	4300000	USD
CY2021Q2	us-gaap	Purchase Commitment Remaining Minimum Amount Committed PurchaseCommitmentRemainingMinimumAmountCommitted	4200000	USD
CY2021Q2	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	18800000	USD
CY2020Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	3700000	USD
	allo	Number Of Shares As Percentage Of Common Shares Outstanding NumberOfSharesAsPercentageOfCommonSharesOutstanding	0.05
CY2021Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	17204935	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21134000	USD
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16770000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	37926000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	30985000	USD
CY2021Q2	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	293594	shares
CY2021Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5300000	USD
CY2021Q2	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	4300000	USD
CY2020Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	2800000	USD
CY2021Q2	us-gaap	Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent	3400000	USD
CY2020Q4	us-gaap	Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent	1100000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19673348	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	26715950	shares

Files In Submission

Name	View Source	Status
0001737287-21-000040-index-headers.html	Edgar Link	pending
0001737287-21-000040-index.html	Edgar Link	pending
0001737287-21-000040.txt	Edgar Link	pending
0001737287-21-000040-xbrl.zip	Edgar Link	pending
allo-20210630.htm	Edgar Link	pending
allo-20210630.xsd	Edgar Link	pending
allo-20210630xex311.htm	Edgar Link	pending
allo-20210630xex312.htm	Edgar Link	pending
allo-20210630xex321.htm	Edgar Link	pending
allo-20210630_cal.xml	Edgar Link	unprocessable
allo-20210630_def.xml	Edgar Link	unprocessable
allo-20210630_htm.xml	Edgar Link	completed
allo-20210630_lab.xml	Edgar Link	unprocessable
allo-20210630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALLO
Allogene Therapeutics, Inc. Stock $allo

2021 Q2 Form 10-Q Financial Statement

#000173728721000040 Filed on August 04, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALLO Allogene Therapeutics, Inc. Stock $allo

2021 Q2 Form 10-Q Financial Statement

#000173728721000040 Filed on August 04, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALLO
Allogene Therapeutics, Inc. Stock $allo